Table 2.
List of studies reporting DBS sampling, serum/plasma-DBS comparative methods, and risk of bias
| Drug | Study | Population type | Sample size | Sampling | Sampling times | Analytical method | DBS-serum/plasma ratio | DBS-serum/plasma comparison methods | Risk of bias (overall) |
|---|---|---|---|---|---|---|---|---|---|
| Rifampin | Martial et al. [29] | TB (pediatric) | 15 | Days 7–10 | 0, 2, 4, and 8 h post-dose | LC-MS/MS | 1.33 | Ratios, Passing–Bablok regression, Bland–Altman plots, predictive performance of plasma from DBS | Low |
| Vu et al. [30] | TB | 12 | ND | 1, 2, and 4 h post-dose | LC-MS/MS | ND | Linear regression, Deming regression | Low | |
| Rifapentine | Parsons et al. [28] | HV | 26 | 1st and 14th dose | 0, 0.5, 1, 2, 4, 5, 8, 12, 24, 34, 48, and 72 h post-dose | LC-MS/MS | ND | Bland–Altman plots | Low |
| Isoniazid | Lee et al. [35] | TB | 10 | ND | ND | UPLC-MS/MS | ND | Passing–Bablok regression, Bland–Altman plot | Low |
| Pyrazinamide | Martial et al. [29] | TB (pediatric) | 15 | Days 7–10 | 0, 2, 4, and 8 h post-dose | LC-MS/MS | 1.23 | Ratios, Passing–Bablok regression, Bland–Altman plots, predictive performance of plasma from DBS | Low |
| Ethambutol | Martial et al. [29] | TB (pediatric) | 15 | Days 7–10 | 0, 2, 4, and 8 h post-dose | LC-MS/MS | 1.96 | Ratios, Passing–Bablok regression, Bland–Altman plots, predictive performance of plasma from DBS | Low |
| Moxifloxacin | Bradmadhi et al. [31] | TB | 15 | After > 3 doses | 2 h post-dose | UPLC-MS/MS | ND | Deming regression, Bland–Altman plots | Low |
| Vu et al. [32] | TB | 6 | Not provided | 0, 2, and 8 h post-dose | LC-MS/MS | ND | Linear regression, Passing–Bablok regression | Low | |
| Linezolid | Baietto et al. [34] | ND | ND | ND | Not provided | UPLC-PDA | ND | Passing–Bablok regressions, Bland–Altman analysis | Low |
| Vu et al. [33] | TB | 8 | After > 7 days | 0, 2, and 8 h post-dose | LC-MS/MS | DBS: 1.20 | Ratios, Passing–Bablok regressions, Bland–Altman analysis | Low | |
| Clarithromycin | Vu et al. [30] | TB | 12 | ND | 0, 2, and 8 h post-dose | LC-MS/MS | ND | Linear regression, Deming regression | Low |
DBS dried blood spots, h hours, HV healthy volunteers, LC-MS/MS liquid chromatography-mass spectrometry/mass spectrometry, ND not described, TB tuberculosis, UPLC-PDA ultra-performance liquid chromatography-photo diode array